These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 22910842)

  • 21. Association of electrochemical skin conductance with neuropathy in chemotherapy-treated patients.
    Mahfouz FM; Park SB; Li T; Timmins HC; Horvath LG; Harrison M; Grimison P; King T; Goldstein D; Mizrahi D
    Clin Auton Res; 2022 Dec; 32(6):497-506. PubMed ID: 36129622
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Rasch-built Overall Disability Scale for patients with chemotherapy-induced peripheral neuropathy (CIPN-R-ODS).
    Binda D; Vanhoutte EK; Cavaletti G; Cornblath DR; Postma TJ; Frigeni B; Alberti P; Bruna J; Velasco R; Argyriou AA; Kalofonos HP; Psimaras D; Ricard D; Pace A; Galiè E; Briani C; Dalla Torre C; Lalisang RI; Boogerd W; Brandsma D; Koeppen S; Hense J; Storey D; Kerrigan S; Schenone A; Fabbri S; Rossi E; Valsecchi MG; Faber CG; Merkies IS; ; Galimberti S; Lanzani F; Mattavelli L; Piatti ML; Bidoli P; Cazzaniga M; Cortinovis D; Lucchetta M; Campagnolo M; Bakkers M; Brouwer B; Boogerd W; Grant R; Reni L; Piras B; Pessino A; Padua L; Granata G; Leandri M; Ghignotti I; Plasmati R; Pastorelli F; Heimans JJ; Eurelings M; Meijer RJ; Grisold W; Lindeck Pozza E; Mazzeo A; Toscano A; Russo M; Tomasello C; Altavilla G; Penas Prado M; Dominguez Gonzalez C; Dorsey SG
    Eur J Cancer; 2013 Sep; 49(13):2910-8. PubMed ID: 23668917
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development and validation of the chemotherapy-induced peripheral neuropathy integrated assessment - oxaliplatin subscale: a prospective cohort study.
    Gu Z; Chen C; Gu J; Song Z; Wei G; Cai G; Shu Q; Zhu L; Zhu W; Deng H; Li S; Chen A; Yin Y; Wu Q; Zhu H; Li G; Dai A; Huo J
    BMC Cancer; 2023 Nov; 23(1):1109. PubMed ID: 37964212
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Chemotherapy-induced peripheral neuropathy; impact on quality of life].
    Scheel A; Beijers AJ; Mols F; Faber CG; Vreugdenhil G
    Ned Tijdschr Geneeskd; 2014; 158():A7455. PubMed ID: 25315326
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Minimal clinically important difference of the EORTC QLQ-CIPN20 for worsening peripheral neuropathy in patients receiving neurotoxic chemotherapy.
    Yeo F; Ng CC; Loh KWJ; Molassiotis A; Cheng HL; Au JSK; Leung KT; Li YC; Wong KH; Suen L; Chan CW; Yorke J; Farrell C; Bandla A; Ang E; Lopez V; Sundar R; Chan A
    Support Care Cancer; 2019 Dec; 27(12):4753-4762. PubMed ID: 30972646
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Repurposing chemotherapy-induced peripheral neuropathy grading.
    Velasco R; Argyriou AA; Cornblath DR; Bruna P; Alberti P; Rossi E; Merkies ISJ; Psimaras D; Briani C; Lalisang RI; Schenone A; Cavaletti G; Bruna J;
    Eur J Neurol; 2024 Dec; 31(12):e16457. PubMed ID: 39282967
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rasch model-based testing of the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Chemotherapy-Induced Peripheral Neuropathy (QLQ-CIPN20) using Alliance for Clinical Trials in Oncology (Alliance) A151408 study data.
    Smith EML; Zanville N; Kanzawa-Lee G; Donohoe C; Bridges C; Loprinzi C; Le-Rademacher J; Yang JJ
    Support Care Cancer; 2019 Jul; 27(7):2599-2608. PubMed ID: 30460399
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Measurement properties of brief neuropathy screening items in cancer patients receiving taxanes, platinums, or proteasome inhibitors.
    Knoerl R; Mazzola E; Mitchell SA; Hong F; Salehi E; McCleary N; Ligibel JA; Reyes K; Berry DL
    J Patient Rep Outcomes; 2021 Sep; 5(1):101. PubMed ID: 34568984
    [TBL] [Abstract][Full Text] [Related]  

  • 29. IMPACT OF CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY ON THE QUALITY OF LIFE IN CANCER PATIENTS.
    Novak M; Miličević J; Bišof V
    Acta Clin Croat; 2022 Mar; 61(1):52-61. PubMed ID: 36530966
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessing chemotherapy-induced peripheral neuropathy with patient reported outcome measures: a systematic review of measurement properties and considerations for future use.
    Li T; Park SB; Battaglini E; King MT; Kiernan MC; Goldstein D; Rutherford C
    Qual Life Res; 2022 Nov; 31(11):3091-3107. PubMed ID: 35596913
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Physical function as a predictor of chemotherapy-induced peripheral neuropathy in patients with pancreatic cancer.
    Lin KY; Chen PS; Lin CF
    BMC Gastroenterol; 2024 May; 24(1):154. PubMed ID: 38711006
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Are we mis-estimating chemotherapy-induced peripheral neuropathy? Analysis of assessment methodologies from a prospective, multinational, longitudinal cohort study of patients receiving neurotoxic chemotherapy.
    Molassiotis A; Cheng HL; Lopez V; Au JSK; Chan A; Bandla A; Leung KT; Li YC; Wong KH; Suen LKP; Chan CW; Yorke J; Farrell C; Sundar R
    BMC Cancer; 2019 Feb; 19(1):132. PubMed ID: 30736741
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute-Common Toxicity Scale.
    Cavaletti G; Frigeni B; Lanzani F; Piatti M; Rota S; Briani C; Zara G; Plasmati R; Pastorelli F; Caraceni A; Pace A; Manicone M; Lissoni A; Colombo N; Bianchi G; Zanna C;
    J Peripher Nerv Syst; 2007 Sep; 12(3):210-5. PubMed ID: 17868248
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development and psychometric evaluation of the chemotherapy-induced peripheral neuropathy assessment tool.
    Tofthagen CS; McMillan SC; Kip KE
    Cancer Nurs; 2011; 34(4):E10-20. PubMed ID: 21242773
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Electroacupuncture for chemotherapy-induced peripheral neuropathy: study protocol for a pilot multicentre randomized, patient-assessor-blinded, controlled trial.
    Kim JH; Kim EJ; Seo BK; Lee S; Lee S; Jung SY; Lee MH; Kim AR; Park HJ; Shin MS; Choi SM
    Trials; 2013 Aug; 14():254. PubMed ID: 23945074
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20.
    Postma TJ; Aaronson NK; Heimans JJ; Muller MJ; Hildebrand JG; Delattre JY; Hoang-Xuan K; Lantéri-Minet M; Grant R; Huddart R; Moynihan C; Maher J; Lucey R;
    Eur J Cancer; 2005 May; 41(8):1135-9. PubMed ID: 15911236
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development and validation of the comprehensive assessment scale for chemotherapy-induced peripheral neuropathy in survivors of cancer.
    Kanda K; Fujimoto K; Mochizuki R; Ishida K; Lee B
    BMC Cancer; 2019 Sep; 19(1):904. PubMed ID: 31506070
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Plasma Lipidomic Profiling Identifies Elevated Triglycerides as Potential Risk Factor in Chemotherapy-Induced Peripheral Neuropathy.
    Yeung N; Li T; Lin HM; Timmins HC; Goldstein D; Harrison M; Friedlander M; Mahon KL; Giles C; Meikle PJ; Park SB; Horvath LG
    JCO Precis Oncol; 2024 Apr; 8():e2300690. PubMed ID: 38691814
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of the psychometric properties of the EORTC chemotherapy-induced peripheral neuropathy questionnaire (QLQ-CIPN20).
    Kieffer JM; Postma TJ; van de Poll-Franse L; Mols F; Heimans JJ; Cavaletti G; Aaronson NK;
    Qual Life Res; 2017 Nov; 26(11):2999-3010. PubMed ID: 28634676
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Peripheral neuropathy in colorectal cancer survivors: the influence of oxaliplatin administration. Results from the population-based PROFILES registry.
    Beijers AJ; Mols F; Tjan-Heijnen VC; Faber CG; van de Poll-Franse LV; Vreugdenhil G
    Acta Oncol; 2015 Apr; 54(4):463-9. PubMed ID: 25417732
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.